Search Blog
Categories
March 2017
M T W T F S S
« Jun    
 12345
6789101112
13141516171819
20212223242526
2728293031  

Tags

Auxellence Announces Sponsored Research on Autonomous Medical Care Opportunities for the TULIP™ Online Health System

By Auxellence Health Corporation

VANCOUVER, BC / ACCESSWIRE / June 22, 2016 / Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF) (“Auxellence” or the “Company”) announces the start of a sponsored research program undertaken by the company’s operator with a major university to evaluate TULIP™ efficacy in normalizing body weight, blood pressure, and blood glucose levels by physiologically interactive computing means.

The program includes neuroscience investigations of the brain-heart dynamics and their accessibility through Tulip™ body-machine interface. The university’s Mathematics and Statistics department will also process the results of the ongoing clinical study of TULIP™ services to physician-supervised patients with cardiometabolic risks, such as high body mass index, hypertension, arrhythmia, and diabetes.

“We are confident that this program will give us additional insights into how computers can interact physiologically with the human body to invoke spontaneous normalization of body weight, blood pressure, and blood glucose levels, without the need for medication, diet, exercise, and other such traditional regimens”, said Sydney Au, Chairman and CEO.

Contact:

Sydney Au, CEO
Auxellence Health Corporation
Email: ceo@auxellence.com
Phone: (604) 780-3311
Website: http://www.auxellence.com
CSE Micro-site: http://thecse.com/en/listings/technology/auxellence-health-corporation

About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management (focusing on weight management and skin conditions).

About Tulip™

TULIP™ is a medical device cleared for sales in Canada and Europe as a blood pressure monitor with interactive protocols. The device enables physiologically interactive health apps useful in testing, tracking, and treating common health conditions. The online system is aimed primarily at “practicing patients” interested in normalizing blood pressure, blood glucose, and body weight. Session schedules, measurement procedures, and conditioning protocols are prescribed automatically by the system from extemporaneous data acquired from the user.

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and on http://thecse.com/en/listings/technology/auxellence-health-corporation.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

SOURCE: Auxellence Health Corporation

ReleaseID: 441481

Alpha Brainwaves for Relaxation Delivered by Alpha Ball

By Alpha Ball

Alpha Ball Is a New Alpha Brainwave Generator That Coaxes User’s Brainwaves into Alpha, Reportedly Increasing Creativity and Relaxation

LOS ANGELES, CA / ACCESSWIRE / June 22, 2016 / During deep relaxation, meditation, or when one’s attention is in the present moment, the brain goes into what’s called an “Alpha state.” This state is characterized by “Alpha waves” being generated by the brain; which are brainwave frequencies ranging between 8 and 12 Hz.

These frequencies are no different from any other source of electrical output, and frequencies from one source can affect frequencies of another. It’s this law of kinetic energy which is the basis for Alpha Ball.

Alpha Ball uses subtle electrical vibrations to emit a field of Alpha waves which transfer to the user. The ball is either held in the hands or floated in bath water, and after 15 minutes of use, users report feelings of relaxation, clarity, and flow of mental insights. “Results from clinical studies showed that the spectrum intensity of the alpha waves nearly doubled with the ball in the hands,” says the website.

The science is backed by considerable research of Tibetan Buddhist monks, whose brainwaves are in Alpha during deep meditation. It has even been reported that generating Alpha brain waves consistently grows the cortical thickness in the hippocampus of the brain which is responsible for feelings of joy, happiness, and compassion.

Rodion Yakoubovsky came up with the concept of Alpha Ball in 2007 when he became interested in the healing effects of tuning forks. “When we have the source of alpha waves in the hands the tiny vibrations are sending the rhythm through the bones to our head and it is helping our brain to tune to the specific ‘deep relaxation’ mode,” says Yakoubovsky.

In 2014/15 he released his first prototype of Alpha ball and so far the feedback has been overwhelmingly positive. After a few more years of clinical trials to substantiate the theory of Alpha wave transference, he’s ready to roll out Alpha Ball to a global audience.

Yakoubovsky is currently seeking backers on Kickstarter to develop and manufacture version 2 of his handheld and waterborne Alpha balls. Both versions will come with USB charging ports and sync to smart phones for music integration with the built-in LEDs.

While science proves what mystics have known for thousands of years, innovative products like Alpha Ball will continue to expand humanity’s level of consciousness. To learn more about Alpha Ball, please visit: https://goo.gl/PqRNf7.

About Alpha Ball:

Alpha Ball is a handheld or waterborne brainwave generator that brings user’s brainwaves into an Alpha frequency between 8 and 12 Hz. The ball reportedly heightens imagination, relaxation, creativity, visualization, memory, learning and concentration.

Contact:

Lydia Pierce
admin@rocketfactor.com
(949) 555-2861

SOURCE: Alpha Ball

ReleaseID: 441490

Will Medical Marijuana Take Biotech Stocks To A New High?

By The Wealthy Venture Capitalist

WINDSOR, ON / ACCESSWIRE / June 22, 2016 / If marijuana brings words like smoke, pot, weed and grass to your mind, it’s time to change that picture to medicine, cure and relief. For the medical marijuana industry, what comes to mind are words like high sales, profit growth potential and stock market catalyst.

Marijuana has been used since the beginning of civilization; the first written record of the use of cannabis dates back to 2727 B.C. The ancient Chinese, Indian, Greek and Roman civilizations used cannabis for pain relief, indigestion and rheumatism, among other medical purposes. Over the centuries, cannabis became notorious as an illicit drug, and it is only in the last 50 years that modern medicine has recognized its value in healing. Research is ongoing on the use of marijuana to ease chronic or severe pain, seizures, muscle spasms, certain aspects of multiple sclerosis, nausea from chemotherapy and weight loss caused by chronic illnesses such as HIV or nerve pain.

The Cannabis Industry has Huge Potential

The cannabis industry is large and growing. More than 25 million Americans are already eligible to buy medical marijuana. The use of marijuana for medical purposes is permitted in 23 states and the District of Columbia. Sales of marijuana touched $5.4 billion in 2015; and this number is expected to surge to more than $6.7 billion in 2016, and explode to almost six times that number to $35 billion by 2020. So, we’re talking about a 600% increase in 4 years. Which other industry affords that rate of growth?

Could Another Surge in Cannabis Stocks be on its Way?

The medical marijuana industry has just received a major boost! In March 2016, GW Pharmaceuticals plc (NASDAQ: GWPH) announced that its cannabis-derived epilepsy drug Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures in the treatment’s first pivotal Phase III study. GW Pharma also has another cannabis-based anti-seizure drug called Sativex.

The primary endpoint was achieved with high statistical significance showing that Epidiolex reduces convulsive seizures in children suffering from Dravet syndrome, a rare and severe form of epilepsy that currently has no FDA-approved treatments.

This is breaking news for the medical industry and is expected to boost shares of biotech companies that have been conducting CBD-related research. And 22nd Century Group Inc. (NYSE MKT: XXII) could be the next outperformer. The company is engaged in the R&D, licensing, manufacturing, and worldwide sales and distribution of innovative and effective patented products. The company’s proprietary genetic engineering technology and plant breeding expertise hold great promise for the medical marijuana industry.

22nd Century has recently signed a strategic partnership with Anandia Labs, a leading player in Canada’s cannabis market. The new cannabis research collaboration – where 22nd Century holds exclusive rights in the U.S. to the genes required for cannabinoid production in the cannabis plant – holds the promise of lucrative commercialization opportunities. Through its innovative research, the Company intends to cost-effectively produce commercial quantities of marijuana-based cannabinoids – including CBD and CBC – that show great promise in treating neurological disorders and other medical diseases. 22nd Century has also opened its own laboratories in New York and it continues with its research collaborations with major universities.

While other cannabis related stocks will benefit from the latest development in convulsive seizures, 22nd Century is the only company that has the ability to upregulate and downregulate cannabinoidsfor the production of unique cannabis plant varieties for the medical marijuana industry. In fact, it is the only company that has patents for the genes that completely eliminate THC in plants, and THC needs to be eliminated in purely medical marijuana varietals and in purely commercial hemp varieties of the plant.

While 22nd Century’s shares closed trading on June 21st at $0.83, analysts have projected a jump in the price to $4.50 in less than a year. That’s a whopping 440% increase!

How are analysts so confident of a surge in 22nd Century’s shares? That’s because historically marijuana shares have skyrocketed on news of advancements in R&D.

Cannabis Stimulates the Stock Market

With thousands of scientists and hundreds of organizations and companies investing in R&D, the cannabis industry has received a great fillip in the past two decades. Stocks of companies associated with medical marijuana tend to spike whenever there is a breakthrough in research. Some stocks soar with the boost in optimism.

Let’s have a look at the last uptrend. In August 2013, the US Department of Justice passed a memo allowing individual states to legalize and regulate marijuana sales. While states were getting ready to legalize the recreational and medical use of cannabis, scientific research had started highlighting its curative properties.

In 2010, GW Pharmaceuticals plc (NASDAQ: GWPH) received approval in the UK for Sativex, a mouth spray that contains two cannabinoids: THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol). This made Sativex the world’s first cannabis-based prescription medicine. On April 10, 2013, the status moved to Schedule 4, which means that controlled drug prescription requirements and safe custody requirements were no longer applicable. In March 2016 as described above, GW Pharma also received approval for its cannabis-derived epilepsy drug, Epidiolex.

Continued scientific study of cannabinoids, the chemicals in marijuana, led the FDA to approve two medications that contained cannabinoid chemicals in pill form. This was a huge breakthrough.

Against the backdrop of good news and expectations of steep sales growth in the cannabis industry, shares responded positively. The stocks that recorded substantial gains in 2014, making early investors jump for joy, included:

United Cannabis (OTCBB: CNAB) – Shares surged 1,025%. This means that if an investor had bought shares for merely $1,000 in 2013, he would have converted that to $11,250 in less than a year! The company was founded to advance the use of cannabinoids in medicine through research, product development and education. It has established affiliate relationships with Harborside and Prana Bio Nutrient Medicinals, among others.

Cannabis Sativa Inc (OTCMKTS: CBDS) – Shares spiked 969%. The company is engaged in the R&D and licensing of natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems.

CannaVEST Corp (OTCMKTS: CANV) – Shares climbed 113%. The company is a manufacturer and distributor of cannabidiol-based products. It is focused on the procurement and wholesale of cannabidiol; and the development, marketing and sale of end-consumer products containing CBD.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist, on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook, as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here:http://clk2.it/k7oF5z.
Follow us on Twitter: @Wealthy_VC
Like us on Facebook:www.facebook.com/WealthyVC
Email:Info@WealthyVentureCapitalist.com

SOURCE: The Wealthy Venture Capitalist

ReleaseID: 441501

The Quest for an Effective Treatment for Pancreatic Cancer

By The Wealthy Venture Capitalist

WINDSOR, ON / ACCESSWIRE / June 22, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight a couple of companies that we believe have immense potential in the quest for an effective pancreatic cancer treatment. 

Companies included: Advanced Medical Isotope (ADMD); Bellicum Pharmaceuticals (BLCM); Celgene (CELG); Halozyme Therapeutics (HALO); ChemCentryx Inc (CCXI); Merrimack (MACK)

According to the National Cancer Institute (NCI), 48,960 new pancreatic cancer cases were diagnosed in the U.S last year with about 80 percent of these resulting in fatalities. Since the pancreas is located deep within the abdomen where tumors are hard to detect, early diagnosis of the disease is difficult and because the cancer can progress very quickly from stage I to stage IV in an average of 1.3 years treatment options are extremely limited.

Currently there are no biomarkers detectable in the blood or bodily fluids which could give a hint of the presence of the disease resulting in a majority of the cases being diagnosed in the late stages. Furthermore pancreatic cancer is the only major cancer with a 5 year survival rate in the single digits at just 7 percent with the NCI projecting that it will surpass both breast cancer and colorectal cancer to become the 2nd leading cause of cancer related deaths in the United States by around 2020. It is therefore no surprise that a considerable number of biotechs such as Advanced Medical Isotope (ADMD) have decided to take a leading role in developing an effective treatment against the disease, exposing investors to the potential of massive gains.

ADMD’s Y-90 RadioGel offers great prospects for treating pancreatic cancer

ADMD is engaged in the development of brachytherapy devices and medical isotopes specifically yttrium-90, which it believes hold the key to dealing with pancreatic cancer. With the constant improvement in technology as well as increasing awareness of the effectiveness of brachytherapy, it has gradually emerged as one of the popular cancer treatment options and is expected to grow to an $8 billion market by next year. The company’s lead product candidate is Y-90 RadioGel which is awaiting the FDA’s clearance to become licensed as a class II medical device.

The simplest explanation of how the Y-90 RadioGel works is that it’s injected into inoperable tumors and then hardens effectively stopping the spread of cancer with the radioactivity effectively killing the cancerous cells while focusing the therapeutic dose to the affected area. This treatment also has a shorter half-life of 2.7 days compared to current treatments which have a half-life of 10 to 65 days, making it safer for both patients and the medical staff.

With estimates from the NCI indicating that spending on pancreatic cancer treatment totaled about $2.6 billion in 2014, ADMD appears to be well positioned to reap huge returns once the FDA gives its approval since it could potentially steal a large share of the market from the existing standard of care. For investors, this means that they could see a dramatic increase in ADMD’s $20 million valuation before the end of the year based on the fact that the treatment is not the only catalyst to look out for.

More pancreatic cancer treatment providers to look at:

Celgene (CELG) which manufacturers drug therapies for cancer and inflammatory disorders currently offers the standard of care for pancreatic cancer with its Abraxane and gemcitabine drug combination. Currently, this combination is being used by half of all newly diagnosed pancreatic cancer cases in the United States and is also enjoying increasing uptake in the European markets.

Furthermore, the company expects the drug to gain more popularity as a result of positive data from the APACT trial expected in 2017 which compares the efficacy of two chemotherapy regimens in patients whose cancer has been removed by surgery. Celgene expects Abraxane to rake in about $1 billion in revenue this year reaffirming the bright prospects of pursuing pancreatic cancer treatments.

Bellicum Pharmaceuticals (BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders is currently in the process of developing a new treatment for pancreatic cancer which it refers to as BPX-601. This new treatment is a GoCAR-T™ product candidate containing Bellicum’s proprietary iMC, (inducible MyD88/CD40) activation switch designed to treat solid tumors expressing prostate stem cell antigen – a cancer antigen expressed in many malignancies such as pancreatic cancer. The initial phase I clinical trial will begin enrolling in the next couple of months with planned indication being for no-resectable pancreatic cancer.

Halozyme Therapeutics (HALO) develops, and commercializes human enzymes used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. This company’s stock has struggled over the past couple of months declining by just about 45 percent on an YTD basis in spite of posting impressive first quarter results. The company is in the process of carrying out phase III clinical trials for one of its product candidates, PEGPH20 for use with Abraxane and gemcitabine for the treatment of pancreatic cancer. Halozyme expects this combination to be effective in treating stage 4 metastatic pancreatic cancer after showing significant treatment effect in 135 subjects during stage one of the study according to data presented at ASCO16 in Chicago.

ChemoCentryx Inc (CCXI) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of orally administered therapeutics to treat cancer, orphan and rare diseases as well as a host of other conditions. One of its lead drug candidates is CCX872 which is currently in phase Ib clinical trials for the treatment of patients with stage 3 or 4 pancreatic cancer. The study aims to evaluate whether orally administered CCX872 can reduce progression of the disease in patients with nonresectable pancreatic cancer undergoing treatment with FOLFIRINOX which is one of the standards of care. Initial progression free data is expected in the second half of 2016 which could signal a huge turning point for the company.

Merrimack (MACK) is a biopharmaceutical company that develops and commercializes medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company is responsible for developing ONIVYDE which is used for the treatment of patients with metastatic cancer of the pancreas after disease progression following gemcitabine-based therapy. In October last year, ONIVYDE received approval from the FDA to treat the condition as well as an orphan drug designation after increasing the survival rates of patients being treated with fluorouracil/leucovorin to 6.1 months compared to 4.2 months without it.  Following this, Merrimack and Baxalta have entered into an exclusive licensing agreement to develop and commercialize ONIVYDE outside of the United States.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist, on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook, as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z.
Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com

SOURCE:  The Wealthy Venture Capitalist

ReleaseID: 441500

New Zealand Energy Corp Announces Results of 2016 Annual General Meeting of Shareholders

Wellington, New Zealand–(Newsfile Corp. – June 22, 2016) – New Zealand Energy Corp. (TSXV: NZ) (“NZEC” or the “Company”) announced today the results of its Annual General Meeting of shareholders held in Wellington, New Zealand on Wednesday 22 June 2016 (NZT).

A total of 111,362,202 common shares representing approximately 48% of the total issued and outstanding common shares were voted at the meeting.

Each of the nominees proposed by management was elected as a director of the Company to hold office until the next annual general meeting, or until successors are elected or appointed:

Nominee Position Percentage of Votes for
James Willis Chairman 99.79%
Mark Dunphy Director 99.81%
Dr. David Llewellyn Director 99.82%

Shareholders voted in favour of all items of business put forward at the meeting, as outlined below:

Motion

Percentage of Votes for

To fix the number of directors of the Company at three (3)
To appoint PricewaterhouseCoopers as Auditors of the Company
To approve the Company’s Amended 2011 Stock Option Plan

95.39%
99.85%
96.63%

The Company Chief Executive Officer, Michael Adams, took the opportunity, as a part of the general business of the meeting, to present some remarks to shareholders on the state of the Company. Mr Adams said, “the last year has been challenging for NZEC, largely because of the drop in oil price from late 2014 to less than US$30 per barrel in January 2016. NZEC has overcome these challenges by demonstrating fiscal responsibility, by being technically and commercially focussed when making decisions, and, throughout by being safe and effective. The result of this is that our oil and gas sales volumes through Q1 and Q2 of 2016 are more than 50% higher than through the same period in 2015.”

“In addition, NZEC has secured another 20 years of tenure on the Waihapa and Ngaere mining permits for the Joint Venture so that the Company now has the security of title we need to warrant substantial investments in re-development. The Tariki mining permit has also been renewed and for the term and work program we requested.”

“When I started with the company in July 2015 it was apparent NZEC could not continue to operate with no positive cash flow, limited available capital, production declining and operating costs flat. We ascertained there was not much room left to further reduce operating costs, so our immediate focus became recovering production rates by spending some of our remaining capital on higher probability of success activities. These activities included;

  • introducing continuous gas-lift at key wells in Waihapa-Ngaere, which has the advantage of collecting data to support and de-risk subsequent developments in this field;
  • initiating the Copper-Moki 1 pool water-flood via injection into Waitapu-2;
  • Changing the pump out at Copper-Moki-2;
  • low cost restoration of Waihapa-1B to temporary production;
  • low cost flow testing of Tariki-1 and 4 for gas production potential”.

“Of these activities, the first 3 of the 5 listed above have been successful, and are the reason NZEC has weathered the very low oil prices in January 2016 without heading to the capital markets or incurring debt. The last two listed above have been disappointing and were always the least certain of the activities we carried out, which is why they were carried out using low cost and temporary equipment.”

“The next year will be focussed on putting what we have learnt from gas-lifting and data collection at Waihapa-Ngaere into practice and on enhancing oil recovery in the Copper-Moki pools. We will also be looking at our exploration permits and carrying out appropriate work in these permits.”

“NZEC has previously referred to the Waihapa Voidage Project. This is being matured into a business case as part of the new Waihapa Enhanced Oil Project. This project leverages our evidence based understanding of the Tikorangi reservoir behaviour to create an investment plan that could materially change long term oil and gas production volumes from the Waihapa-Ngaere assets. This work is in the final stages of preparation and will be reviewed by the Waihapa-Ngaere Joint Venture in the next quarter. I am excited by the transformational opportunities this particular project, if approved, may provide to NZEC.”

“The results of the water-flood in the Copper-Moki-1 pool continue to be positive. We are looking to expand the Copper-Moki-1 pool water-flood and its application to the Copper-Moki-2 pool is being investigated.”

“Appraisal and exploration activities have necessarily taken a lower priority in the past year and we are returning effort to these activities through the next quarter so that we will be ready to progress on these at short notice should the oil price continue to rise.”

“The past year has been about demonstrating that NZEC is now a smart and effective onshore Operator. The next year will be about transforming NZEC to growth and creating value from our existing assets on the back of smart investments.”

“By this time next year NZEC could be a very different company again and I hope that our shareholders are willing to stay with us through this interesting and exciting period.”

On behalf of the Board of Directors

James Willis

Chairman

New Zealand Energy Contacts

Email: info@newzealandenergy.com
Website: www.newzealandenergy.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This document contains certain forward- looking information and forward-looking statements (“forward-looking statements”). The Company notes that such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond NZEC’s control, the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, imprecision of reserve estimates, environmental risks, operational risks in exploration and development, competition from other industry participants, the lack of availability of qualified personnel or management, stock market volatility and the ability to access sufficient capital from internal and external sources. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward looking information.

As such, readers are cautioned not to place undue reliance on the forward looking information, as no assurance can be provided as to future results, levels of activity or achievements. All forward-looking statements are made as of the date of this document, except as required by applicable law, the Company does not undertake any obligation to publicly update or to revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Smart Kitty, Automatic Litter Box for Cats, is Officially Launched

By Smart Kitty

The Automatic and Self-Cleaning Litter Box Helps Keep a Cat’s Bathroom Place Clean and Low on Odor, and Alerts the Owner Via an App When the Litter Box’s Container Must Be Emptied

LOS ANGELES, CA / ACCESSWIRE / June 22, 2016 / Piotr Kielkowski is pleased to announce the launch of his innovative and revolutionary Smart Kitty – automatic litter box for cats. The new litter box helps maintain a clean aroma kitty litter space and makes it even easier for pet owners to take care of their beloved cats.

Kielkowski and the rest of the team that is responsible for this new product began with a simple problem: how to make litter boxes cleaner, easier, and more efficient. From this small seed, Smart Kitty’s development team introduced ground-breaking technology to create a unique product.

“It all starts when the cat enters the box; dynamic sensors immediately register when it enters and trigger the automatic brush as they leave,” noted Kielkowski, adding that without any action on the owner’s part, the brush scoops the droppings and puts them into a special odor-proof sealed container. “The self-cleaning Smart Kitty alerts the cat’s owner via a free app for iPhone and Android every few days to a week when the special container needs to be discarded. The high tech elements make the process streamlined and hands-off.”

By fully automating the litter box, Kielkowski said, Smart Kitty allows owners to enjoy their lives, while staying fully informed via their phones.

“With comfort, ease, and quality for both owners and cats, Smart Kitty has used technology in a bold and ground-breaking way that is sure to influence design for years to come,” he said.

Even though the automatic litter box was just recently launched, Kielkowski said it is already getting a lot of attention from cat owners who are grateful to have an easier way to tend to one of the least-popular parts of sharing a home with a feline fur baby.

In order to help pay for the production costs associated with the new Smart Kitty litter box, Kielkowski recently launched a fundraiser on Indiegogo. He hopes to raise $40,000 through crowdfunding.

To learn more about Smart Kitty and/or to make a donation to the fundraiser on Indiegogo, please visit https://www.indiegogo.com/projects/smart-kitty-automatic-litter-box-for-cats#/.

About Smart Kitty:

Smart Kitty is a top-quality automatic and self-cleaning litter box. The newly-released littler box features dynamic sensors that “know” when a cat enters the box. One the kitty exits the litter box a brush will automatically scoop the droppings and puts them into a sealed container.

Contact:

Daisy Lamb
admin@rocketfactor.com
(949) 555-2861

SOURCE: Smart Kitty

ReleaseID: 441489

New Zealand Energy Corp Announces Results of 2016 Annual General Meeting of Shareholders

By New Zealand Energy Corp.

WELLINGTON, NEW ZEALAND / ACCESSWIRE / June 22, 2016 / New Zealand Energy Corp. (TSXV: NZ) (“NZEC” or the “Company”) announced today the results of its Annual General Meeting of shareholders held in Wellington, New Zealand on Wednesday 22 June 2016 (NZT).

A total of 111,362,202 common shares representing approximately 48% of the total issued and outstanding common shares were voted at the meeting.

Each of the nominees proposed by management was elected as a director of the Company to hold office until the next annual general meeting, or until successors are elected or appointed:

Shareholders voted in favour of all items of business put forward at the meeting, as outlined below:

The Company Chief Executive Officer, Michael Adams, took the opportunity, as a part of the general business of the meeting, to present some remarks to shareholders on the state of the Company. Mr Adams said, “The last year has been challenging for NZEC, largely because of the drop in oil price from late 2014 to less than US$30 per barrel in January 2016. NZEC has overcome these challenges by demonstrating fiscal responsibility, by being technically and commercially focussed when making decisions, and, throughout by being safe and effective. The result of this is that our oil and gas sales volumes through Q1 and Q2 of 2016 are more than 50% higher than through the same period in 2015.”

“In addition, NZEC has secured another 20 years of tenure on the Waihapa and Ngaere mining permits for the Joint Venture so that the Company now has the security of title we need to warrant substantial investments in re-development. The Tariki mining permit has also been renewed and for the term and work program we requested.”

“When I started with the company in July 2015 it was apparent NZEC could not continue to operate with no positive cash flow, limited available capital, production declining and operating costs flat. We ascertained there was not much room left to further reduce operating costs, so our immediate focus became recovering production rates by spending some of our remaining capital on higher probability of success activities. These activities included;

  • introducing continuous gas-lift at key wells in Waihapa-Ngaere, which has the advantage of collecting data to support and de-risk subsequent developments in this field;
  • initiating the Copper-Moki 1 pool water-flood via injection into Waitapu-2;
  • Changing the pump out at Copper-Moki-2;
  • low cost restoration of Waihapa-1B to temporary production;
  • low cost flow testing of Tariki-1 and 4 for gas production potential.”

“Of these activities, the first 3 of the 5 listed above have been successful, and are the reason NZEC has weathered the very low oil prices in January 2016 without heading to the capital markets or incurring debt. The last two listed above have been disappointing and were always the least certain of the activities we carried out, which is why they were carried out using low cost and temporary equipment.”

“The next year will be focused on putting what we have learned from gas-lifting and data collection at Waihapa-Ngaere into practice and on enhancing oil recovery in the Copper-Moki pools. We will also be looking at our exploration permits and carrying out appropriate work in these permits.”

“NZEC has previously referred to the Waihapa Voidage Project. This is being matured into a business case as part of the new Waihapa Enhanced Oil Project. This project leverages our evidence based understanding of the Tikorangi reservoir behaviour to create an investment plan that could materially change long term oil and gas production volumes from the Waihapa-Ngaere assets. This work is in the final stages of preparation and will be reviewed by the Waihapa-Ngaere Joint Venture in the next quarter. I am excited by the transformational opportunities this particular project, if approved, may provide to NZEC.”

“The results of the water-flood in the Copper-Moki-1 pool continue to be positive. We are looking to expand the Copper-Moki-1 pool water-flood and its application to the Copper-Moki-2 pool is being investigated.”

“Appraisal and exploration activities have necessarily taken a lower priority in the past year and we are returning effort to these activities through the next quarter so that we will be ready to progress on these at short notice should the oil price continue to rise.”

“The past year has been about demonstrating that NZEC is now a smart and effective onshore Operator. The next year will be about transforming NZEC to growth and creating value from our existing assets on the back of smart investments.”

“By this time next year NZEC could be a very different company again and I hope that our shareholders are willing to stay with us through this interesting and exciting period.”

On behalf of the Board of Directors

“James Willis”

Chairman

New Zealand Energy Contacts

Email: info@newzealandenergy.com
Website: www.newzealandenergy.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This document contains certain forward- looking information and forward-looking statements (“forward-looking statements”). The Company notes that such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond NZEC’s control, the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, imprecision of reserve estimates, environmental risks, operational risks in exploration and development, competition from other industry participants, the lack of availability of qualified personnel or management, stock market volatility and the ability to access sufficient capital from internal and external sources. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward looking information.

As such, readers are cautioned not to place undue reliance on the forward looking information, as no assurance can be provided as to future results, levels of activity or achievements. All forward-looking statements are made as of the date of this document, except as required by applicable law, the Company does not undertake any obligation to publicly update or to revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: New Zealand Energy Corp.

ReleaseID: 441499

Creative Institute, a K-12 School, Announces Its Launch

By Creative Institute

The School’s Mission is to Provide a Great Education to K-12 Students With Disabilities and Challenges

ATLANTIC CITY, NJ / ACCESSWIRE / June 22, 2016 / The Creative Institute, a school that focuses on providing children in kindergarten through 12th grade with a quality education, recently announced its launch. Founded by Crystal Mays, the Atlantic City-based school will specialize in teaching students with disabilities and challenges.

According to a statement released by Mays, the purpose of the Creative Institute is to give students a chance at developing initiative, creativity, and responsibility, especially because these qualities are best learned in a school environment. The Creative Institute will focus on fostering positive, sensible, and fulfilling relationships between students and teachers by encouraging them to engage in activities that they consider useful. The school was founded on a special initiative: founder Mays wanted to develop a learning system that encouraged knowledge while being mindful of past and present technological, social, and economic conditions.

“My goal is to educate students with a 21st century learning environment,” said Mays. “This campaign is geared toward students with disabilities and challenges. The focus of this campaign is to give back to the community by providing 21st century education platforms.”

At this time, Mays has taken her campaign to Indiegogo, where she hopes to raise the necessary funds to bring the Creative Institute to life. Mays is offering a variety of perks in exchange for contributions. For example, every person who donates $50 will receive a thank you letter from the K-12 students.

Individuals interested in learning more about the Creative Institute and its work can visit the school’s Indiegogo page for additional information.

About the Creative Institute:

The incredible Creative Institute has the qualities that families most treasure–initiative, creativity, and responsibility, all of which are best learned in sustained relationships as teachers and learners engage in activities they consider useful, sensible and fulfilling. The 21st Century Learning Initiative is transnational movement committed to the development of learning systems that apply and extend a growing knowledge of the learning process and are suited to current and future technological, social and economic conditions. The Creative Institute’s goal is to provide students with a 21st century learning environment. For more information, please visit https://www.indiegogo.com/projects/creative-institute-k-12-seed-money#/.

Contact:

Jaime Cannon
admin@rocketfactor.com
(949) 555-2861

SOURCE: Creative Institute

ReleaseID: 441491

Theralase Files Dosimetry Fibre Optic Cage Patent Application

By Theralase Technologies Inc.

TORONTO, ON / ACCESSWIRE / June 22, 2016 / Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSXV: TLT) (OTC: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs“) to destroy cancer, announced today that it has filed a US patent for its proprietary Dosimetry Fibre Optic Cage (“DFOC“) technology.

DFOC technology allows Theralase to precisely monitor and remotely control laser light energy delivered to hollow organs, such as the bladder, when undergoing treatment with Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC“).

The patent application is entitled, “Fiber Optic-Based Photodynamic Treatment Delivery and Irradiance Monitoring System” and has been licenced to Theralase under a royalty agreement with Princess Margaret Cancer Centre, University Health Network (“UHN“).”

The current methodology planned for the Phase Ib clinical study for NMIBC involves:

  • Intravesical installation of a sterile water based solution of TLD-1433 via catheter into the bladder of a patient
  • Allowing the solution of TLD-1433 to absorb into any resident bladder cancer tumours for approximately sixty minutes
  • Voiding the bladder and flushing the bladder twice with sterile water to remove any excess TLD-1433 solution not absorbed by bladder tumours
  • Admitting the patient into the operating room and administrating a general anesthetic
  • Insertion of a rigid cystoscope into the urethra of a patient
  • Filling the bladder with sterile water to provide shape to the bladder
  • Inserting the DFOC technology into the bladder via the cystoscope’s working channel
  • Once resident in the bladder, the DFOC is deployed (like an umbrella) to strategically place optical detectors at twelve predetermined locations in the bladder to monitor and remotely control the amount of laser light delivered, providing a uniform distribution of laser light to the bladder wall

Dr. Lothar Lilge, Staff Scientist at UHN and inventor of the DFOC technology stated that, “The purpose of this research is to determine if we can deliver a uniform distribution of TLD-1433 solution to the bladder lesions and a uniform distribution of laser light to the bladder wall. If so, there should be a uniform activation of TLD-1433 absorbed by the cancerous lesions providing a safer, more tolerable and ultimately more effective destruction of bladder tumours than previously achieved. This hypothesis will be tested clinically in a Phase Ib clinical study for NMIBC to commence pending Investigational Testing Authorization (“ITA“) approval by Health Canada.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “The Company is a strong supporter of Dr. Lilge’s research at UHN. Dr. Lilge’s latest invention is focused on precisely controlling the amount of laser light received by the bladder wall and should increase the safety, tolerability and efficacy of the TLD-1433 treatments in the destruction of bladder cancer.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSXV: TLT) (OTC: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT“) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs“), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 441352

Moviemaker and Whiskey Aficionado Charles Bodenhamer Announces Release of New Film Mr. Daniel

By Mr. Daniel

The Feature Film Tells the Fascinating Story of One of America’s Most Famous Whiskey Makers

LOS ANGELES, CA / ACCESSWIRE / June 22, 2016 / Charles Bodenhamer, a writer and self-described fan of whiskey, is pleased to announce the release of his new feature film Mr. Daniel. As Bodenhamer noted, the story tells the tale about Mr. Daniel whiskey and how one of America’s most famous whiskey-makers got his start.

The new feature film is already getting a lot of attention from people in both the whiskey and historical spaces. As Bodenhamer, a former resident of Texas who now resides in Newcastle, Australia, noted, if there is any man in history who is worthy of a movie to tell his story, it is Mr. Daniel.

“This feature film gives him a voice, and it’s also a glimpse through a window to an easier time where square shooters were prevalent and a man’s handshake actually meant something,” Bodenhamer said, adding that Mr. Daniel will take movie-goers on a ride like they have never experienced before. “I reckon every man leaving the theater will wish he was Mr. Daniel and by golly the woman by his side will wish he was too.”

From Mr. Daniel’s first breath of scotch whiskey, to his own humble beginnings in the art of distilling, to his last sip of his finest achievement, the movie promises to be a fascinating account of the man’s life.

“Along the way you’ll meet some other memorable characters from history and discover why he was also quite the ladies’ man,” Bodenhamer said.

In order to help pay for the production costs associated with making Mr. Daniel, Bodenhamer recently launched a fundraiser on Indiegogo. He hopes to use the power of crowdfunding to raise $1,000,000 towards his new movie.

To learn more about Bodenhamer’s new feature film Mr. Daniel and/or to make a donation to his Indiegogo fundraiser, please visit https://www.indiegogo.com/projects/mr-daniel#/.

About Mr. Daniel:

In the last one hundred years, one of Tennessee’s most famous trademarks has been its whiskey. Mr. Daniel, who became one of the nation’s most recognizable distillers, got his start as a young boy in the backwoods of middle Tennessee. Although his name is universally known around the world, the story of his life has been shrouded in mystery and legend. This incredibly insightful and entertaining new feature film will take viewers through the highs and lows of Mr. Daniel’s life and shed some light on the mysteries that surround this legendary man.

Contact:

Ricardo Tyler
admin@rocketfactor.com
(949) 555-2861

SOURCE: Mr. Daniel

ReleaseID: 441494